Table 2 Validation and performance of Model 1 (RMH) and Model 2 (RMH + NLR50) in comparison with the updated Model 3 (NCIS).
From: Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials
Characteristics | Model 1: RMH | Model 2: RMH + NLR50 | Model 3: NCIS | |||
|---|---|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
RMH score | ||||||
0 | 1 | 1 | 1 | |||
1 | 1.28 (0.96–1.70) | 0.099 | 1.29 (0.96–1.72) | 0.087 | 1.22 (0.91–1.63) | 0.189 |
2 | 2.27 (1.62–3.17) | <0.001 | 2.16 (1.54–3.02) | <0.001 | 2.13 (1.51–3.00) | <0.001 |
3 | 4.14 (2.62–6.53) | <0.001 | 4.05 (2.56–6.39) | <0.001 | 3.80 (2.40–6.02) | <0.001 |
NLR50a | ||||||
≤3.4 | – | – | 1 | – | – | |
>3.4 | – | – | 1.38 (1.08–1.76) | 0.009 | – | – |
ECOG PS | ||||||
0 | – | – | – | – | 1 | |
1 | – | – | – | – | 1.59 (1.24–2.04) | <0.001 |
Tumour type | ||||||
Breast | – | – | – | – | 1 | |
GI malignancies | – | – | – | – | 3.06 (2.16–4.35) | <0.001 |
Others | – | – | – | – | 1.81 (1.32–2.45) | <0.001 |
Harrell C-statistic | 0.62 (0.60–0.64) | 0.63 (0.62–0.65) | 0.67 (0.65–0.69) | |||
3-month AUC (95% CI)b | 0.72 (0.63–0.79) | 0.71 (0.62–0.79) | 0.71 (0.63–0.79) | |||
6-month AUC (95% CI)b | 0.65 (0.59–0.71) | 0.67 (0.61–0.73) | 0.71 (0.65–0.78) | |||
iAUC (95% CI)b | 0.67 (0.61–0.72) | 0.69 (0.64–0.73) | 0.71 (0.65–0.76) | |||
